Summary of ERS/ATS severe asthma task force recommendations
| Question | Recommendation | Strength | Quality of evidence |
| 1 | Suggest an anti-IL-5 strategy as add-on therapy for adult patients with severe uncontrolled asthma with an eosinophilic phenotype and for those with severe corticosteroid-dependent asthma | Conditional | Low |
| 2 | Suggest that a blood eosinophil cut-point ≥150 per µL can be used to guide anti-IL-5 initiation in adult patients with severe asthma and a history of prior asthma exacerbations | Conditional | Low |
| 3 | Suggest using a blood eosinophil cut-off ≥260 per µL to identify adolescents (>12 years) and adults with severe allergic asthma more likely to benefit from anti-IgE treatment | Conditional | Low |
| Suggest using a FENO cut-off ≥19.5 ppb to identify adolescents (>12 years) and adults with severe allergic asthma more likely to benefit from anti-IgE treatment | Conditional | Low | |
| 4 | For children, adolescents and adults with severe asthma uncontrolled despite GINA step 4–5 or NAEPP step 5 therapies, recommend the addition of tiotropium | Strong | Moderate |
| 5 | Suggest a trial of macrolide treatment to reduce asthma exacerbations in adult asthma subjects on GINA/NAEPP step 5 therapy that remain persistently symptomatic or uncontrolled | Conditional | Low |
| Suggest against the use of chronic macrolide treatment in children and adolescents with severe uncontrolled asthma | Conditional | Low | |
| 6 | Suggest dupilumab as add-on therapy for adult patients with severe eosinophilic asthma and for those with severe corticosteroid-dependent asthma regardless of eosinophil levels | Conditional | Low |
Reproduced and modified from [6].